Orforglipron, an oral non-peptide GLP-1 receptor agonist developed by Eli Lilly and Company, is currently in Phase 3 clinical trials [1]. Eli Lilly has indicated that it anticipates filing for approval of orforglipron in 2026, with a potential launch soon after [2]. The drug is being investigated for the treatment of obesity and type 2 diabetes [1].
When might Orforglipron become available?
Eli Lilly aims to submit an approval application for orforglipron in 2026. Following regulatory review, the drug could potentially launch thereafter [2].
What is Orforglipron and how does it work?
Orforglipron is an orally administered, small-molecule GLP-1 receptor agonist [1]. Unlike injectable GLP-1 receptor agonists, it is taken by mouth. It works by activating the glucagon-like peptide-1 (GLP-1) receptor, which plays a role in regulating appetite and glucose metabolism [1][3].
What are the current clinical trial stages for Orforglipron?
Orforglipron is presently undergoing Phase 3 clinical trials. These trials are designed to gather more comprehensive data on the drug's efficacy and safety in a larger patient population [1].
What is the difference between Orforglipron and injectable GLP-1 agonists?
The primary difference is the route of administration. Orforglipron is an oral pill, while many other GLP-1 receptor agonists, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), are administered via injection [1].
Who is developing Orforglipron?
Orforglipron is being developed by Eli Lilly and Company [1].
What conditions is Orforglipron intended to treat?
The drug is being studied for the treatment of obesity and type 2 diabetes [1].
Are there any safety concerns or side effects known for Orforglipron?
As Orforglipron is still in clinical trials, comprehensive safety data is being collected. Common side effects associated with GLP-1 receptor agonists, in general, can include gastrointestinal issues such as nausea, vomiting, and diarrhea [3]. Specific side effect profiles for Orforglipron will become clearer as Phase 3 trials progress and upon regulatory review [1].
What are Eli Lilly's other obesity or diabetes medications?
Eli Lilly also produces tirzepatide (Mounjaro, Zepbound), a dual GLP-1 and GIP receptor agonist, for type 2 diabetes and obesity, and semaglutide (Trulicity) for type 2 diabetes [3].
Sources:
1. https://drugpatentwatch.com/company/eli-lilly-and-company
2. https://drugpatentwatch.com/drug/orforglipron
3. https://drugpatentwatch.com/drugs/glp-1-receptor-agonists